Brighter AB (publ) announced that the Actiste device and the newly developed Actiste Mini device have received market approval from the Thai FDA, which is a prerequisite to start importing and marketing the products. A cellular transmission approval process, which is a requirement for activation and use of the products, is under way. Further information about Brighter’s commercial plan and strategy for Thailand will follow during the spring.